Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Dyslipidemia-Pipeline Review, H2 2016

Dyslipidemia-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Dyslipidemia-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Dyslipidemia-Pipeline Review, H2 2016', provides an overview of the Dyslipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dyslipidemia

The report reviews pipeline therapeutics for Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Dyslipidemia therapeutics and enlists all their major and minor projects

The report assesses Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Dyslipidemia

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Dyslipidemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 6

Dyslipidemia Overview 7

Therapeutics Development 8

Dyslipidemia-Therapeutics under Development by Companies 10

Dyslipidemia-Therapeutics under Investigation by Universities/Institutes 15

Dyslipidemia-Pipeline Products Glance 16

Dyslipidemia-Products under Development by Companies 20

Dyslipidemia-Products under Investigation by Universities/Institutes 28

Dyslipidemia-Companies Involved in Therapeutics Development 29

Dyslipidemia-Therapeutics Assessment 90

Drug Profiles 107

Dyslipidemia-Dormant Projects 289

Dyslipidemia-Discontinued Products 306

Dyslipidemia-Product Development Milestones 312

Appendix 324

List of Figures

Number of Products under Development for Dyslipidemia, H2 2016 22

Number of Products under Development for Dyslipidemia-Comparative Analysis, H2 2016 23

Number of Products under Development by Companies, H2 2016 24

Number of Products under Investigation by Universities/Institutes, H2 2016 29

Comparative Analysis by Late Stage Development, H2 2016 30

Comparative Analysis by Clinical Stage Development, H2 2016 31

Comparative Analysis by Early Stage Products, H2 2016 32

Assessment by Monotherapy Products, H2 2016 104

Assessment by Combination Products, H2 2016 105

Number of Products by Top 10 Targets, H2 2016 106

Number of Products by Stage and Top 10 Targets, H2 2016 106

Number of Products by Top 10 Mechanism of Actions, H2 2016 111

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 111

Number of Products by Routes of Administration, H2 2016 117

Number of Products by Stage and Routes of Administration, H2 2016 117

Number of Products by Molecule Types, H2 2016 119

Number of Products by Stage and Molecule Types, H2 2016 119

List of Tables

Number of Products under Development for Dyslipidemia, H2 2016 22

Number of Products under Development for Dyslipidemia-Comparative Analysis, H2 2016 23

Number of Products under Development by Companies, H2 2016 25

Number of Products under Development by Companies, H2 2016 (Contd..1) 26

Number of Products under Development by Companies, H2 2016 (Contd..2) 27

Number of Products under Development by Companies, H2 2016 (Contd..3) 28

Number of Products under Investigation by Universities/Institutes, H2 2016 29

Comparative Analysis by Late Stage Development, H2 2016 30

Comparative Analysis by Clinical Stage Development, H2 2016 31

Comparative Analysis by Early Stage Development, H2 2016 32

Comparative Analysis by Unknown Stage Development, H2 2016 33

Products under Development by Companies, H2 2016 34

Products under Development by Companies, H2 2016 (Contd..1) 35

Products under Development by Companies, H2 2016 (Contd..2) 36

Products under Development by Companies, H2 2016 (Contd..3) 37

Products under Development by Companies, H2 2016 (Contd..4) 38

Products under Development by Companies, H2 2016 (Contd..5) 39

Products under Development by Companies, H2 2016 (Contd..6) 40

Products under Development by Companies, H2 2016 (Contd..7) 41

Products under Investigation by Universities/Institutes, H2 2016 42

Dyslipidemia-Pipeline by Acasti Pharma Inc., H2 2016 43

Dyslipidemia-Pipeline by AFFiRiS AG, H2 2016 44

Dyslipidemia-Pipeline by Akcea Therapeutics Inc, H2 2016 45

Dyslipidemia-Pipeline by Allergan Plc, H2 2016 46

Dyslipidemia-Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 47

Dyslipidemia-Pipeline by Amgen Inc., H2 2016 48

Dyslipidemia-Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 49

Dyslipidemia-Pipeline by AstraZeneca Plc, H2 2016 50

Dyslipidemia-Pipeline by BASF SE, H2 2016 51

Dyslipidemia-Pipeline by BCWorld Pharm Co. Ltd., H2 2016 52

Dyslipidemia-Pipeline by BioRestorative Therapies, Inc., H2 2016 53

Dyslipidemia-Pipeline by Cadila Pharmaceuticals Limited, H2 2016 54

Dyslipidemia-Pipeline by Cardax, Inc., H2 2016 55

Dyslipidemia-Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016 56

Dyslipidemia-Pipeline by Cerenis Therapeutics Holding SA, H2 2016 57

Dyslipidemia-Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 58

Dyslipidemia-Pipeline by CJ HealthCare Corp., H2 2016 59

Dyslipidemia-Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 60

Dyslipidemia-Pipeline by CymaBay Therapeutics, Inc., H2 2016 61

Dyslipidemia-Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 62

Dyslipidemia-Pipeline by Daiichi Sankyo Company, Limited, H2 2016 63

Dyslipidemia-Pipeline by Debiopharm International SA , H2 2016 64

Dyslipidemia-Pipeline by Eli Lilly and Company, H2 2016 65

Dyslipidemia-Pipeline by Esperion Therapeutics, Inc., H2 2016 66

Dyslipidemia-Pipeline by Gemphire Therapeutics Inc., H2 2016 67

Dyslipidemia-Pipeline by GlaxoSmithKline Plc, H2 2016 68

Dyslipidemia-Pipeline by Golden Biotechnology Corp., H2 2016 69

Dyslipidemia-Pipeline by HanAll Biopharma Co., Ltd., H2 2016 70

Dyslipidemia-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 71

Dyslipidemia-Pipeline by Huons Co., Ltd., H2 2016 72

Dyslipidemia-Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 73

Dyslipidemia-Pipeline by Innovent Biologics, Inc., H2 2016 74

Dyslipidemia-Pipeline by IPCA Laboratories Limited, H2 2016 75

Dyslipidemia-Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 76

Dyslipidemia-Pipeline by Jenrin Discovery, Inc., H2 2016 77

Dyslipidemia-Pipeline by JW Pharmaceutical Corporation, H2 2016 78

Dyslipidemia-Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 79

Dyslipidemia-Pipeline by Kotobuki Pharmaceutical Co., Ltd., H2 2016 80

Dyslipidemia-Pipeline by Kowa Company, Ltd., H2 2016 81

Dyslipidemia-Pipeline by Kymab Limited, H2 2016 82

Dyslipidemia-Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 83

Dyslipidemia-Pipeline by LG Life Science LTD., H2 2016 84

Dyslipidemia-Pipeline by Lipicard Technologies Limited, H2 2016 85

Dyslipidemia-Pipeline by Lipigon Pharmaceuticals AB, H2 2016 86

Dyslipidemia-Pipeline by LipimetiX Development Inc, H2 2016 87

Dyslipidemia-Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016 88

Dyslipidemia-Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 89

Dyslipidemia-Pipeline by Merck & Co., Inc., H2 2016 90

Dyslipidemia-Pipeline by Nimbus Therapeutics, LLC, H2 2016 91

Dyslipidemia-Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 92

Dyslipidemia-Pipeline by Omeros Corporation, H2 2016 93

Dyslipidemia-Pipeline by Pfizer Inc., H2 2016 94

Dyslipidemia-Pipeline by Pharmena SA, H2 2016 95

Dyslipidemia-Pipeline by Protalix BioTherapeutics, Inc., H2 2016 96

Dyslipidemia-Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 97

Dyslipidemia-Pipeline by Sancilio & Company, Inc., H2 2016 98

Dyslipidemia-Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 99

Dyslipidemia-Pipeline by Thetis Pharmaceuticals LLC, H2 2016 100

Dyslipidemia-Pipeline by Torrent Pharmaceuticals Limited, H2 2016 101

Dyslipidemia-Pipeline by Yuhan Corporation, H2 2016 102

Dyslipidemia-Pipeline by Zydus Cadila Healthcare Limited, H2 2016 103

Assessment by Monotherapy Products, H2 2016 104

Assessment by Combination Products, H2 2016 105

Number of Products by Stage and Target, H2 2016 107

Number of Products by Stage and Mechanism of Action, H2 2016 112

Number of Products by Stage and Route of Administration, H2 2016 118

Number of Products by Stage and Molecule Type, H2 2016 120

Dyslipidemia-Dormant Projects, H2 2016 303

Dyslipidemia-Dormant Projects (Contd..1), H2 2016 304

Dyslipidemia-Dormant Projects (Contd..2), H2 2016 305

Dyslipidemia-Dormant Projects (Contd..3), H2 2016 306

Dyslipidemia-Dormant Projects (Contd..4), H2 2016 307

Dyslipidemia-Dormant Projects (Contd..5), H2 2016 308

Dyslipidemia-Dormant Projects (Contd..6), H2 2016 309

Dyslipidemia-Dormant Projects (Contd..7), H2 2016 310

Dyslipidemia-Dormant Projects (Contd..8), H2 2016 311

Dyslipidemia-Dormant Projects (Contd..9), H2 2016 312

Dyslipidemia-Dormant Projects (Contd..10), H2 2016 313

Dyslipidemia-Dormant Projects (Contd..11), H2 2016 314

Dyslipidemia-Dormant Projects (Contd..12), H2 2016 315

Dyslipidemia-Dormant Projects (Contd..13), H2 2016 316

Dyslipidemia-Dormant Projects (Contd..14), H2 2016 317

Dyslipidemia-Dormant Projects (Contd..15), H2 2016 318

Dyslipidemia-Dormant Projects (Contd..16), H2 2016 319

Dyslipidemia-Discontinued Products, H2 2016 320

Dyslipidemia-Discontinued Products (Contd..1), H2 2016 321

Dyslipidemia-Discontinued Products (Contd..2), H2 2016 322

Dyslipidemia-Discontinued Products (Contd..3), H2 2016 323

Dyslipidemia-Discontinued Products (Contd..4), H2 2016 324

Dyslipidemia-Discontinued Products (Contd..5), H2 2016 325

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acasti Pharma Inc.

AFFiRiS AG

Akcea Therapeutics Inc

Allergan Plc

Alnylam Pharmaceuticals, Inc.

Amgen Inc.

Arisaph Pharmaceuticals, Inc.

AstraZeneca Plc

BASF SE

BCWorld Pharm Co. Ltd.

BioRestorative Therapies, Inc.

Cadila Pharmaceuticals Limited

Cardax, Inc.

Catabasis Pharmaceuticals, Inc.

Cerenis Therapeutics Holding SA

Chong Kun Dang Pharmaceutical Corp.

CJ HealthCare Corp.

Connexios Life Sciences Pvt. Ltd.

CymaBay Therapeutics, Inc.

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Debiopharm International SA

Eli Lilly and Company

Esperion Therapeutics, Inc.

Gemphire Therapeutics Inc.

GlaxoSmithKline Plc

Golden Biotechnology Corp.

HanAll Biopharma Co., Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

Huons Co., Ltd.

Hyundai Pharmaceutical Co., Ltd.

Innovent Biologics, Inc.

IPCA Laboratories Limited

Jeil Pharmaceutical Co., Ltd.

Jenrin Discovery, Inc.

JW Pharmaceutical Corporation

Kissei Pharmaceutical Co., Ltd.

Kotobuki Pharmaceutical Co., Ltd.

Kowa Company, Ltd.

Kymab Limited

Kyorin Pharmaceutical Co., Ltd.

LG Life Science LTD.

Lipicard Technologies Limited

Lipigon Pharmaceuticals AB

LipimetiX Development Inc

Lotus Pharmaceutical Co., Ltd.

Matinas BioPharma Holdings, Inc.

Merck & Co., Inc.

Nimbus Therapeutics, LLC

Nippon Chemiphar Co., Ltd.

Omeros Corporation

Pfizer Inc.

Pharmena SA

Protalix BioTherapeutics, Inc.

Regeneron Pharmaceuticals Inc

Sancilio & Company, Inc.

Takeda Pharmaceutical Company Limited

Thetis Pharmaceuticals LLC

Torrent Pharmaceuticals Limited

Yuhan Corporation

Zydus Cadila Healthcare Limited

Dyslipidemia Therapeutic Products under Development, Key Players in Dyslipidemia Therapeutics, Dyslipidemia Pipeline Overview, Dyslipidemia Pipeline, Dyslipidemia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com